Fintepla: payments to doctors
Payments that named Fintepla as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.5M
- Providers
- 6,171
- Transactions
- 33,562
- Average per transaction
- $134
The per-transaction average — $134 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,171 providers the average total is $731, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| UCB, Inc. | $3,915,617 | 86.8% |
| Zogenix Inc. | $323,444 | 7.2% |
| UCB SA | $152,791 | 3.4% |
| UCB Biosciences Inc. | $114,430 | 2.5% |
| Nippon Shinyaku Co.,ltd | $4,646 | 0.1% |